Assessment of CAR- or CD46-Dependent adenoviral vector-mediated trail gene therapy in clinical adenocarcinoma lung cancer cells

Oncology

Volumn 77, Issue 6, 2010, Pages 366-377

  Wang, Yong ^a   Ma, Lingdi ^a   Wang, Shizhong ^a   Bao, Yongyi ^a   Ni, Cheng ^a   Guan, Naifu ^a   Zhao, Jianzhong ^a   Fan, Xiaolong ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Apoptosis; Gene therapy; Lung cancer; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

ADENOVIRUS VECTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GREEN FLUORESCENT PROTEIN; MEMBRANE COFACTOR PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CAR RECEPTOR; CD46 PROTEIN, HUMAN; VIRUS RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; ADENOCARCINOMA; ADENOVIRUS; GENE VECTOR; GENETICS; LUNG TUMOR; MIDDLE AGED; PHYSIOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ADENOVIRIDAE; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD46; APOPTOSIS; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, VIRUS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 73649116040     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000275831     Document Type: Article

References (39)

1. Ashkenazi A, Herbst RS: The immune system: an ally in TRAIL-based cancer therapy? J Clin Invest 2008; 118: 1979-1990.
2. Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430. (Pubitemid 37328939)
3. Spierings DC, De Vries EG, Timens W, Groen HJ, Boezen MH, De Jong S: Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003; 9: 3397-3405. (Pubitemid 37082735)
4. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821. (Pubitemid 27366733)
5. Yang F, Shi P, Xi X, Yi S, Li H, Sun Q, Sun M: Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC). Med Oncol 2006; 23: 191-204. (Pubitemid 43780302)
6. Kim CY, Jeong M, Mushiake H, Kim BM, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, et al: Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther 2006; 13: 330-338. (Pubitemid 43223102)
7. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323. (Pubitemid 27114163)
8. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins-alpha v-3 and-alphav-5promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
9. Qin M, Chen S, Yu T, Escuadro B, Sharma S, Batra RK: Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenografts. Clin Cancer Res 2003; 9: 4992-4999. (Pubitemid 37323306)
10. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT: Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001; 61: 813-817. (Pubitemid 32174383)
11. Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R: The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998; 9: 2363-2373. (Pubitemid 28523985)
12. Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM: The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 2001; 98: 15191-15196. (Pubitemid 34013991)
13. Walters RW, Freimuth P, Moninger TO, Ganske I, Zabner J, Welsh MJ: Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell 2002; 110: 789-799. (Pubitemid 35283966)
14. Gaggar A, Shayakhmetov DM, Lieber A: CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408-1412. (Pubitemid 37466191)
15. Nilsson M, Ljungberg J, Richter J, Kiefer T, Magnusson M, Lieber A, Widegren B, Karlsson S, Fan X: Development of an adenoviral vector system with adenovirus serotype 35 tropism, efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 2004; 6: 631-641. (Pubitemid 40228079)
16. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A: Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567-2583. (Pubitemid 30117566)
17. Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F, Xu R: Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005; 65: 1687-1692. (Pubitemid 40478593)
18. Voortman J, Resende TP, Abou EI Hassan MA, Giaccone G, Kruyt FA: TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 2007; 6: 2103-2112. (Pubitemid 47052501)
19. Mittereder N, Keith LM, Bruce CT: Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509. (Pubitemid 26339054)
20. Duchence GM, Eady JH, Pera MF: A panel of human lung carcinoma lines: establishment, properties and common characteristics. Br J Cancer 1987; 56: 287-293.
21. Fujino H, Kondo K, Miyoshi T, Ishikura H, Takahashi Y, Nagao T, Sakiyama S, Monden Y: Establishment of patient-like SCID mouse model by orthotopically implanting primary cultured cells from surgically-resected lung cancer tissues. Oncol Rep 2003; 10: 1709-1715.
22. Rhee HJ, Kim GY, Huh JW, Kim SW, Na DS: Annexin I is a stress protein induced by heat, oxidative stress and a sulfhydryl-reactive agent. Eur J Biochem 2000; 267: 3220-3225. (Pubitemid 30341148)
23. Nakao K, Otsuki Y, Akao Y, Ito Y, Marukawa O, Tachibana S, Kawakami M, Sasaki S: The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis. Med Electron Microsc 2000; 33: 44-50.
24. Wang Y, Wang SZ, Bao YY, Ni C, Guan NF, Zhao JZ, Salford LG, Widegren B, Fan X: Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers. J Mol Histol 2006; 37: 153-160. (Pubitemid 44532065)
25. Marttila M, Persson D, Gustafsson D, Liszewski MK, Atkinson JP, Wadell G, Arnberg N: CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol 2005; 79: 14429-14436. (Pubitemid 41552740)
26. Murray KP, Mathure S, Kaul R, Khan S, Carson LF, Twiggs LB, Martens MG, Kaul A: Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 2000; 76: 176-182. (Pubitemid 30067192)
27. Anderson BD, Nakamura T, Russell SJ, Peng KW: High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004; 64: 4919-4926. (Pubitemid 38924538)
28. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, Matsutani M: Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 2004; 21: 53-56. (Pubitemid 39518146)
29. Yu H, Gong XQ, Luo XY, Han W, Hong G, Singh B, Tang CK: Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF induced a transient effect on EGFR-mediated signaling pathways. Cancer Biol Ther 2008; 7: 1818-1828.
30. Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, et al: Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 2003; 94: 50-56. (Pubitemid 36575858)
31. Sonnweber B, Dlaska M, Skvortsov S, Dirnhofer S, Schmid T, Hilbe W: High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J Clin Pathol 2006; 59: 255-259. (Pubitemid 43344885)
32. Wu FX, Luo Y, Cao J, Zhao YN, Yuan WP, Li Y, Su JJ: Expression and significance of epidermal growth factor receptor variant type III in hepatocellular carcinoma. Chin J Cancer 2005; 24: 166-169.
33. Cavenee WK: Genetics and new approaches to cancer therapy. Carcinogenesis 2002; 23: 683-686. (Pubitemid 34567504)
34. Sun SY, Yue P, Hong WK, Lotan R: Augmentation of tumor necrosis factor-related apoptosis- inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1- adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through upregulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000; 60: 7149-7155. (Pubitemid 32059197)
35. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA: Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis- inducing ligand (TRAIL) gene. Cancer Res 2001; 61: 3330-3338. (Pubitemid 32695022)
36. Sun SY, Yue P, Zhou JY, Wang Y, Choi Kim HR, Lotan R, Wu GS: Overexpression of Bcl2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 2001; 280: 788-797. (Pubitemid 32924499)
37. Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K: Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAILinduced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 2007; 282: 29831-29846. (Pubitemid 350035287)
38. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lee D, et al: Deathreceptor O-glycosylation controls tumorcell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13: 1070-1077. (Pubitemid 47517508)
39. Ricci MS, Jin Z, Dews M, Yu D, Thomas TA, Dicker DT: Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004; 24: 8541-8555. (Pubitemid 39245075)